Cargando…
Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective st...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491630/ https://www.ncbi.nlm.nih.gov/pubmed/28258416 http://dx.doi.org/10.1245/s10434-017-5818-2 |
_version_ | 1783247171385032704 |
---|---|
author | Seeberg, Lars Thomas Brunborg, Cathrine Waage, Anne Hugenschmidt, Harald Renolen, Anne Stav, Ingunn Bjørnbeth, Bjørn A. Borgen, Elin Naume, Bjørn Brudvik, Kristoffer W. Wiedswang, Gro |
author_facet | Seeberg, Lars Thomas Brunborg, Cathrine Waage, Anne Hugenschmidt, Harald Renolen, Anne Stav, Ingunn Bjørnbeth, Bjørn A. Borgen, Elin Naume, Bjørn Brudvik, Kristoffer W. Wiedswang, Gro |
author_sort | Seeberg, Lars Thomas |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System(®), and bone marrow was sampled for DTC analyses just prior to hepatic resection. The presence of one or more tumor cells was scored as CTC/DTC-positive. Following resection of the primary tumor, the lymph nodes (LNs) were examined by routine histopathological examination. RESULTS: A total of 140 patients were included in this study; 38 patients (27.1%) were negative at the primary colorectal LN examination (N0). CTCs were detected in 12.1% of all patients; 5.3% of patients in the N0 group and 14.7% of patients in the LN-positive (N+) group (p = 0.156), with the LN-positive group (N+) consisting of both N1 and N2 patients. There was a significant difference in recurrence-free survival (RFS) when analysing the N0 group versus the N+ group (p = 0.007) and CTC-positive versus CTC-negative patients (p = 0.029). In multivariate analysis, CTC positivity was also significantly associated with impaired overall survival (OS) [p = 0.05], whereas DTC positivity was not associated with survival. CONCLUSION: In this cohort of resectable CLM patients, 27% had primary N0 colorectal cancer. Assessment of CTC in addition to nodal status may contribute to improved classification of patients into high- and low-risk groups, which has the potential to guide and improve treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-017-5818-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5491630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-54916302017-07-13 Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases Seeberg, Lars Thomas Brunborg, Cathrine Waage, Anne Hugenschmidt, Harald Renolen, Anne Stav, Ingunn Bjørnbeth, Bjørn A. Borgen, Elin Naume, Bjørn Brudvik, Kristoffer W. Wiedswang, Gro Ann Surg Oncol Colorectal Cancer OBJECTIVE: The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting. METHODS: In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System(®), and bone marrow was sampled for DTC analyses just prior to hepatic resection. The presence of one or more tumor cells was scored as CTC/DTC-positive. Following resection of the primary tumor, the lymph nodes (LNs) were examined by routine histopathological examination. RESULTS: A total of 140 patients were included in this study; 38 patients (27.1%) were negative at the primary colorectal LN examination (N0). CTCs were detected in 12.1% of all patients; 5.3% of patients in the N0 group and 14.7% of patients in the LN-positive (N+) group (p = 0.156), with the LN-positive group (N+) consisting of both N1 and N2 patients. There was a significant difference in recurrence-free survival (RFS) when analysing the N0 group versus the N+ group (p = 0.007) and CTC-positive versus CTC-negative patients (p = 0.029). In multivariate analysis, CTC positivity was also significantly associated with impaired overall survival (OS) [p = 0.05], whereas DTC positivity was not associated with survival. CONCLUSION: In this cohort of resectable CLM patients, 27% had primary N0 colorectal cancer. Assessment of CTC in addition to nodal status may contribute to improved classification of patients into high- and low-risk groups, which has the potential to guide and improve treatment strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-017-5818-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-03-03 2017 /pmc/articles/PMC5491630/ /pubmed/28258416 http://dx.doi.org/10.1245/s10434-017-5818-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Colorectal Cancer Seeberg, Lars Thomas Brunborg, Cathrine Waage, Anne Hugenschmidt, Harald Renolen, Anne Stav, Ingunn Bjørnbeth, Bjørn A. Borgen, Elin Naume, Bjørn Brudvik, Kristoffer W. Wiedswang, Gro Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title | Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title_full | Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title_fullStr | Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title_full_unstemmed | Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title_short | Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases |
title_sort | survival impact of primary tumor lymph node status and circulating tumor cells in patients with colorectal liver metastases |
topic | Colorectal Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491630/ https://www.ncbi.nlm.nih.gov/pubmed/28258416 http://dx.doi.org/10.1245/s10434-017-5818-2 |
work_keys_str_mv | AT seeberglarsthomas survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT brunborgcathrine survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT waageanne survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT hugenschmidtharald survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT renolenanne survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT stavingunn survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT bjørnbethbjørna survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT borgenelin survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT naumebjørn survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT brudvikkristofferw survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases AT wiedswanggro survivalimpactofprimarytumorlymphnodestatusandcirculatingtumorcellsinpatientswithcolorectallivermetastases |